Journals / Gülhane Tıp Dergisi / 2021 / Cilt: 63 - Sayı: 4

Potential of epigenetic biomarker O6-methylguanine-DNA methyltransferase gene in glioma

Pages
274–279
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

High percentages of gliomas, 92.7% harboring methylated MGMT promoter, indicate that it is a potential epigenetic biomarker for glioma detection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Glioblastomas are the most malignant gliomas in adults with the median survival of 15 months only.
📊
Key Findings & Data:O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme which overcomes the alkylating chemotherapy effect resulting in chemo-resistance.
💡
Conclusion & Impact:High percentages of gliomas, 92.7% harboring methylated MGMT promoter, indicate that it is a potential epigenetic biomarker for glioma detection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aims: Glioblastomas are the most malignant gliomas in adults with the median survival of 15 months only. O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme which overcomes the alkylating chemotherapy effect resulting in chemo-resistance. Methylation at the MGMT gene promoter reduces the gene expression and enhances chemo- sensitivity in cancer treatments. Therefore, this study aimed to screen MGMT methylation status for a potential epigenetic biomarker in glioma detection and treatmentin glioma patients at Hospital Universiti Sains Malaysia. Methods: Forty-one glioma paraffin-embedded glioma tissue samples consisting of grade 2 (n=11), 3 (n=10) and 4 (n=20) were analyzed in this retrospective study. The extracted DNA was subjected to bisulfite treatment and the methylation status was determined via methylation- specific polymerase chain reaction targeting the MGMT gene promoter. Results: It was observed that 92.7% of the glioma samples showed methylated and 7.3% unmethylated MGMT promoter. All grade 2 and grade 3 gliomas showed methylation, compared to 85% of grade 4 (p=0.183). More older glioma patients (>40 years) had methylation compared to younger patients (≤40 years) (95.8% vs 88.2%) (p=0.357). More males had methylation compared to females (96% vs 87.5%) (p=0.308). Conclusions: MGMT promoter methylation was found predominant in older (>40 years) male patients with grade 2 and 3 gliomas. High percentages of gliomas, 92.7% harboring methylated MGMT promoter, indicate that it is a potential epigenetic biomarker for glioma detection.

🔖

Cite This Article

AHMAD, F., SHAMSUDDİN, S., GOH, W. C., MURALİ, R., IDRİS, B., IDRİS, Z. (2022). Potential of epigenetic biomarker O6-methylguanine-DNA methyltransferase gene in glioma. Gülhane Tıp Dergisi, Cilt: 63 - Sayı: 4, 274–279. https://ajindex.com/articles/526786

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int. 2010;107:799-807
  2. Brain and spinal tumour. Med J Malaysia. 2014;69:261- 267
  3. Dong X, Noorbakhsh A, Hirshman BR, et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER- based analysis. Neurooncol Pract. 2016;3:29-38
  4. Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus. 2014;37:E11
  5. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167-223
  6. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 2009;29:3759-3768
  7. Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900-2908
  8. Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP. Depletion of O6-alkylguanine- DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993;67:1299-1302
  9. Lau D, Magill ST, Aghi MK. Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg Focus. 2014;37:E15
  10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003
  11. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31:4085-4091
  12. Ray S, Bonafede MM, Mohile NA. Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population. Am Health Drug Benefits. 2014;7:140-149
  13. Wang J, Zhao YY, Li JF, et al. IDH1 mutation detection by droplet digital PCR in glioma. Oncotarget. 2015;6:39651- 39660
  14. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-820
  15. Yoshioka M, Matsutani T, Hara A, et al. Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. Oncotarget. 2018;9:27728-27735
  16. Boisselier B, Marie Y